Oncology Drug Development – FDA Suggests New Trial Designs for Accelerated Approvals
16503
news-template-default,single,single-news,postid-16503,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Oncology Drug Development – FDA Suggests New Trial Designs for Accelerated Approvals

Oncology Drug Development – FDA Suggests New Trial Designs for Accelerated Approvals

The FDA officials urge sponsors to initiate a single randomized trial prior to receiving accelerated approval or conduct a single-group accelerated-approval study in patients without other available therapy, concurrently with a randomized trial with the potential to demonstrate clinical benefit in patients who have received fewer treatments.
(Ref: Fashoyin-Aje LA et al, N Engl J Med. Sep 21,2022)

#oncologyresearch #oncologytrials #drugdevelopment #clinicalresearch #fdaapproval # #fda

https://www.linkedin.com/feed/update/urn:li:activity:6982350995125092352

No Comments

Sorry, the comment form is closed at this time.